North America, particularly the United States, dominates the global GLP-1 receptor agonist market
1,2 Following a meal, GLP-1 facilitates glucose-dependent insulin secretion from pancreatic -cells, suppresses glucagon release from -cells, and slows gastric emptying, all of which moderate glucose excursions following nutrient intake
These components enable: Higher molecular stability Longer half-life Improved receptor selectivity Reduced enzymatic degradation As triple agonist pipelines expand, retatrutide reshape global peptide API demand through increased reliance on high-barrier specialty amino acids
Notably, in murine pancreatic -cells, GLP-1 can activate both G proteins Gs and Gq, whereas GIP selectively activates Gs (45)
How much weight can I expect to lose
UK perioperative guidance for GLP-1based therapies advises individualised assessment